This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jurklies, B Articles by Bornfeld, N Search for Related Content PubMed PubMed Citation Articles by Jurklies, B Articles by Bornfeld, N

Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma

¹ Department of Ophthalmology, Univ-Hospital Essen, Germany
² Department of Ophthalmology, Univ-Hospital Lübeck, Germany

Correspondence to:
Correspondence to:
Bernhard Jurklies, MD, Department of Ophthalmology, Universitätsklinikum Essen, Hufelandstrasse 55, D-45122 Essen, Germany;
bernhard.jurklies{at}uni-essen.de

Aim: To investigate the safety and efficacy of photodynamic therapy with verteporfin in patients with choroidal haemangioma.

Methods: A non-randomised, prospective clinical investigation of 19 patients with symptomatic circumscribed choroidal haemangioma was performed. Unsuccessful pretreatment (external beam irradiation, laser photocoagulation) was performed in four patients. Patients were included when (1) subretinal exudation involving the fovea, (2) a decrease in visual function, and (3) additional symptoms (for example, metamorphopsia) were present. Photodynamic therapy (PDT) was performed with verteporfin at a concentration of 6 mg/m² body surface area and a light dose of 100 J/cm² at 692 nm.

Results: The mean follow up time was 10.6 months (2–24 months). The mean number of treatment sessions was 2.15 (range 1–5). Visual acuity improved by at least one line in 73.3%, by at least two lines in 42.1%, was stable in 21.1%, and decreased by one line in 5.2% of the patients. Exudation was completely resolved in 94.8% of the cases. Regression of tumour height was documented in all 19 tumours. Patients receiving any pretreatment before PDT, a visual acuity of 0.1 and less, a history of more than 30 months, and no significant response after the first PDT session, did not show any significant improvement. Cox regression analysis revealed that the number of PDT treatment sessions was inversely associated with the improvement in visual acuity of at least two lines. No recurrences and no local or systemic side effects were observed during the follow up time.

Conclusion: PDT using verteporfin is a safe and effective therapy for the treatment of symptomatic choroidal haemangioma even in tumours located beneath the fovea.

Keywords: verteporfin; photodynamic therapy; choroidal haemangioma

This article has been cited by other articles:

				A Lipski, N Bornfeld, and B Jurklies Photodynamic therapy with verteporfin in paediatric and young adult patients: long-term treatment results of choroidal neovascularisations Br. J. Ophthalmol., May 1, 2008; 92(5): 655 - 660. [Abstract] [Full Text] [PDF]

				A. Aizman, P. T. Finger, U. Shabto, A. Szechter, and A. Berson Palladium 103 (103Pd) Plaque Radiation Therapy for Circumscribed Choroidal Hemangioma With Retinal Detachment Arch Ophthalmol, November 1, 2004; 122(11): 1652 - 1656. [Abstract] [Full Text] [PDF]

				A D Singh, P K Kaiser, J E Sears, M Gupta, P A Rundle, and I G Rennie Photodynamic therapy of circumscribed choroidal haemangioma Br. J. Ophthalmol., November 1, 2004; 88(11): 1414 - 1418. [Abstract] [Full Text] [PDF]